Corporate development

Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sleep, Monitor Deloitte, Growth, Patient, Acquisition, Cancer, Spacecraft, Senior, Therapy, Bain, Partner, GW Pharmaceuticals, ADC, Bain & Company, Corporate development, Jazz Pharmaceuticals, Pharmaceutical industry

Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).

Key Points: 
  • Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).
  • “I am delighted to welcome George to the Mythic team,” said Brian Fiske, Ph.D., Chief Scientific Officer and Co-Founder at Mythic Therapeutics.
  • Prior to that, Dr. Eliades spent over 20 years at Bain & Company and Monitor Group, advising biotech clients in corporate strategy, M&A, growth and digital-driven transformations.
  • Dr. Eliades stated, “I’m incredibly excited to join Mythic and work toward improving outcomes for more cancer patients through our pipeline of innovative ADCs.

Celigo Appoints Rod Hamlin as SVP of Partnerships and Corporate Development

Retrieved on: 
Wednesday, March 27, 2024
Software, Artificial Intelligence, Data Management, Technology, Supply Chain Management, Online Retail, Retail, Other Technology, Automation, Synthetic media, Growth, Improper integral, Partnership, AI, Senior, International development, Redis, Machine learning, Silk, Corporate development, Generative

Celigo , the leading integration platform as a service (iPaaS) for business and IT users, today announced the appointment of Rod Hamlin as Senior Vice President of Partnerships and Corporate Development.

Key Points: 
  • Celigo , the leading integration platform as a service (iPaaS) for business and IT users, today announced the appointment of Rod Hamlin as Senior Vice President of Partnerships and Corporate Development.
  • Hamlin brings to Celigo a proven track record of cultivating strategic partnerships, fostering channel development, and expanding global alliances.
  • Before joining Celigo, Hamlin served as Senior Vice President of Global Development and General Manager of EMEA for H2O.ai, the open-source leader in Generative AI and machine learning, where he dedicated three years to developing pivotal global partnerships and nurturing channels and cloud alliances.
  • Previously, Hamlin ran global business development at Silk, a leading data virtualization platform provider.

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Research, Financial management, Mirati Therapeutics, Medication, Regeneron Pharmaceuticals, Alexion Pharmaceuticals, CFO, General counsel, Patient, Pharming, Strategic planning, Arena Pharmaceuticals, Acquisition, Bristol Myers Squibb, Drug, MBA, Marketing, Drug development, Access, Disorder, Corporate development

Aaron Ondrey joins Rocket as Chief Financial Officer, bringing more than 20 years of experience in financial management, strategic planning, commercial finance, capital allocation and mergers and acquisitions having held multiple finance leadership positions across the pharma and biotech industry.

Key Points: 
  • Aaron Ondrey joins Rocket as Chief Financial Officer, bringing more than 20 years of experience in financial management, strategic planning, commercial finance, capital allocation and mergers and acquisitions having held multiple finance leadership positions across the pharma and biotech industry.
  • Prior to Mirati, Mr. Ondrey also held senior leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals.
  • The key appointments within Rocket’s existing corporate leadership team are as follows:
    Kinnari Patel, Pharm.D., MBA, has been appointed President, Head of R&D and Chief Operating Officer.
  • J.D., has been appointed General Counsel & Chief Corporate Officer, and will lead Legal, Compliance, and Corporate Development.

Boston Children’s Hospital and NRG Energy celebrate $1 million milestone, thanks to the Choose to Give program

Retrieved on: 
Thursday, March 28, 2024
Hospitals, Other Energy, Utilities, Philanthropy, Energy, Health, Fund Raising, General Health, Other Philanthropy, Electricity, Boston Children's Hospital, Government, Learning, Partnership, NRG, Hospital trust, Research, Rombach, Hospital, NRG Energy, Multimedia, Corporate development, Policy, Health insurance

NRG Energy, one of the leading suppliers of energy and home services in Massachusetts, today celebrated surpassing $1 million in contributions to Boston Children’s Hospital from its charitable program, Choose to Give .

Key Points: 
  • NRG Energy, one of the leading suppliers of energy and home services in Massachusetts, today celebrated surpassing $1 million in contributions to Boston Children’s Hospital from its charitable program, Choose to Give .
  • “We’re delighted to recognize NRG’s generous support,” said Michael Bornhorst, Vice President, Corporate Development, Leadership Giving & Special Events at Boston Children’s Hospital Trust.
  • “Our longstanding partnership with Boston Children’s Hospital is extremely important to us at NRG,” said Mike Rombach, Vice President and General Manager of NRG Home.
  • Customers interested in learning more about the NRG electricity plan benefiting Boston Children’s Hospital, or to enroll can visit picknrg.com/bch .

Q-SYS Promotes Jason Moss to Vice President, Marketing & Ecosystem

Retrieved on: 
Thursday, March 21, 2024
Technology, Audio, Video, Software, Networks, Internet, Hardware, Microsoft, Intel, Ecosystem, Senior, QSC, Retirement, Corporate development, Management

Q-SYS , a division of QSC LLC, is pleased to announce the promotion of Jason Moss to Vice President of Marketing & Ecosystem.

Key Points: 
  • Q-SYS , a division of QSC LLC, is pleased to announce the promotion of Jason Moss to Vice President of Marketing & Ecosystem.
  • Concurrently, after nearly a decade of dedicated service, Chris Humphrey, Senior Vice President of Marketing, has announced his retirement for May.
  • Since joining Q-SYS in 2020 as Vice President of Corporate Development and Alliances and becoming a member of the executive team, Moss has significantly impacted the company’s leadership.
  • “I am so proud of our achievements and have full confidence in Jason to elevate this department, anticipating continued success for Q-SYS."

R. Dane Mauldin named NIQ Chief Transformation Officer

Retrieved on: 
Wednesday, March 20, 2024
Professional Services, Marketing, Retail, Communications, Data Analytics, Other Retail, Dane, TransUnion, Full, GfK, Corporate development, Heart, EVP, Management

NIQ, the world’s leading global consumer intelligence company, today announced that R. Dane (Dane) Mauldin has joined the company as Chief Transformation Officer effective March 18, 2024.

Key Points: 
  • NIQ, the world’s leading global consumer intelligence company, today announced that R. Dane (Dane) Mauldin has joined the company as Chief Transformation Officer effective March 18, 2024.
  • He joins NIQ from TransUnion, where he was EVP and Chief Operations Officer, and previously EVP and Chief Product Officer.
  • Curtis Miller, who held the role most recently, has been appointed Chief Strategy Officer, accountable for Strategy and Corporate Development.
  • We’ve made strong progress in our transformation thus far, including significant work to integrate GfK and NIQ and Dane is uniquely positioned to help us accelerate our plans,” said Jim Peck, Executive Chairman and Chief Executive Officer.

Solu Therapeutics Appoints Michael Boretti, Ph.D., as Chief Business Officer

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Growth, Cytotoxicity, Cell, Disease, Business, University, CBO, Chimera, Therapy, Biological engineering, Corporate development, Management

Solu Therapeutics, a biotechnology company focused on developing therapeutics to eliminate disease-driving cells using its CyTaCTM (Cytotoxicity Targeting Chimera) platform, today announced the appointment of Michael I. Boretti, Ph.D., as Chief Business Officer (CBO).

Key Points: 
  • Solu Therapeutics, a biotechnology company focused on developing therapeutics to eliminate disease-driving cells using its CyTaCTM (Cytotoxicity Targeting Chimera) platform, today announced the appointment of Michael I. Boretti, Ph.D., as Chief Business Officer (CBO).
  • Dr. Boretti brings over 15 years of biotechnology leadership experience to Solu, including an extensive track record of company-building and deal-making across diverse therapeutic indications.
  • As CBO, he will lead Solu’s business development strategy, strategic financing and alliance management activities.
  • “As an accomplished, collaborative corporate strategist, Mike is an ideal addition to the Solu leadership team as we work to maximize the value and impact of our platform.”

Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Piper Sandler Companies, Goldman Sachs, CFO, Patient, Endeavour, Pharming, Bank, Sale, IPO, Senior, Therapy, BofA Securities, Multimedia, Corporate development, RBC Capital Markets, Management

as President and Vishaal Turakhia as Chief Financial Officer (CFO).

Key Points: 
  • as President and Vishaal Turakhia as Chief Financial Officer (CFO).
  • Both Dr. Kariuki and Mr. Turakhia are established life sciences executives with extensive strategic, operational, and financial experience.
  • View the full release here: https://www.businesswire.com/news/home/20240314798010/en/
    “We’re preparing for an important year ahead at Endeavor BioMedicines and I’m delighted that both Enoch and Vishaal are joining the company,” said John Hood, Ph.D., Co-founder, CEO and Chairman, Endeavor BioMedicines.
  • As a result of Dr. Kariuki’s new role as President, he will transition off of Endeavor BioMedicines’ Board of Directors.

Unstructured Raises $40M Series B From Menlo Ventures, Databricks Ventures, IBM Ventures and NVIDIA to Make Enterprise Data LLM-ready

Retrieved on: 
Thursday, March 14, 2024
Software, Technology, Artificial Intelligence, Data Management, Aircraft, Azure, Organization, Software as a service, BCV, Partnership, Databricks, RAG, Menlo Ventures, AI, AWS, LLM, Architecture, Hallucination, Machine learning, NVIDIA, Corporate development, Cryptocurrency

Tim Tully of Menlo Ventures joined the board of directors as part of the investment, which brings the company’s total capital raised to $65 million.

Key Points: 
  • Tim Tully of Menlo Ventures joined the board of directors as part of the investment, which brings the company’s total capital raised to $65 million.
  • Unstructured will leverage this new injection of capital to grow its team and accelerate its development of data preprocessing tooling for LLMs.
  • This includes files such as emails, documents, images, videos, and other data organizations historically haven’t been able to use at scale, in conjunction with machine learning.
  • Addressing this critical gap, Unstructured is the first and only company that can ingest and pre-process all unstructured data into formats ready for use with foundation models.

Caleres Names Liz Dunn SVP of Corporate Development and Strategic Communications

Retrieved on: 
Thursday, March 14, 2024
Footwear, Fashion, Online Retail, Retail, Other Retail, Department Stores, Specialty, Liz Claiborne, Bear Stearns, Multimedia, CAL, Research, Corporate development, Economics, Growth, Communication, Spelman College, Gap Inc., Management

Caleres (NYSE: CAL), a market-leading portfolio of consumer-driven footwear brands, today announced that Liz Dunn has joined the company as senior vice president of corporate development and strategic communications.

Key Points: 
  • Caleres (NYSE: CAL), a market-leading portfolio of consumer-driven footwear brands, today announced that Liz Dunn has joined the company as senior vice president of corporate development and strategic communications.
  • View the full release here: https://www.businesswire.com/news/home/20240314235926/en/
    Caleres Names Liz Dunn SVP of Corporate Development and Strategic Communications (Photo: Business Wire)
    In this newly created role, Dunn will leverage her nearly 30 years’ experience spanning equity research, investment banking, consulting, and finance to ensure Caleres aligns its growth ambitions and strategic communications with delivering shareholder value.
  • Dunn will report to Caleres president and CEO Jay Schmidt.
  • “Liz has been working closely with Caleres for the last year as a consultant to provide a thoughtful perspective on our strategic and financial plans.